RSV診断薬市場：製品、方法、最終用途別-2025-2030年の世界予測

RSV診断薬市場は、2023年に10億7,000万米ドルと評価され、2024年には11億7,000万米ドルに達すると予測され、CAGR 9.20％で成長し、2030年には19億8,000万米ドルに達すると予測されています。

呼吸器合胞体ウイルス（RSV）診断は、乳幼児、高齢者、免疫不全者に影響を及ぼすため、ヘルスケアにおいて極めて重要です。調査手法の範囲は、迅速抗原検出検査（RADT）、RT-PCRのような分子診断、血清学的アッセイのような多様な検査手法を包含しています。これらはRSV感染の早期発見と管理において極めて重要な役割を果たし、RSV感染のトランスミッションと重症化を抑制します。RSV診断薬の必要性は、ウイルス感染に対する世界の意識の高まりと、ポイントオブケア検査技術の進歩に後押しされて急上昇しています。エンドユーススコープには主に病院、診断研究所、診療所が含まれ、効率的で迅速な判断が患者のケアに不可欠です。RSV有病率の上昇、分散型診断ソリューションに対する需要の高まり、ヘルスケアインフラの進歩などの要因により、市場は成長する見込みです。しかし、高度な診断ツールの高コスト、検査感度のばらつき、規制上のハードルなどの課題が成長の妨げとなる可能性があります。費用対効果が高く高感度な代替診断ツールの開発や、RSV検査の精度と効率を高める人工知能の統合にはビジネスチャンスがあります。企業は、技術主導の製品開発に投資し、ヘルスケアのニーズが急増している成長著しい新興国市場に進出することで、こうした機会を活用することができます。研究とイノベーションは、分子診断の強化、携帯型ポイントオブケア機器の開発、予測診断のためのバイオインフォマティクスの探求に焦点を当てることができます。有望な見通しとは裏腹に、市場はジェネリック診断法との競合、潜在的なバイオセーフティ問題、低所得地域における経済的制約などの限界に直面しています。企業への戦略的提言としては、ヘルスケアプロバイダーとパートナーシップを結び、より広範な製品展開を図ること、研究開発に注力しイノベーションを推進すること、戦略的プランニングを通じて進化する規制へのコンプライアンスを確保することなどが挙げられます。RSV診断薬市場の性質はダイナミックであり、個別化されたヘルスケアソリューションへの動向が、継続的な適応とイノベーションの必要性を強調しています。

市場力学：急速に進化するRSV診断薬市場の主要市場インサイトを公開

RSV診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 人口における呼吸器感染症の有病率の上昇
  • 感染症の早期診断に対する意識の高まり
  • シンシチアルウイルス診断薬の承認取得の増加
• 市場抑制要因
  • RSV診断薬に関連する製品回収問題
• 市場機会
  • 呼吸器合胞体ウイルス診断の進歩
  • ゲノミクスおよびプロテオミクス研究の成長
• 市場の課題
  • 現在のRSV診断製品および手順に関連する限界

ポーターの5つの力：RSV診断薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：RSV診断薬市場における外部からの影響の把握

外部マクロ環境要因は、RSV診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析RSV診断薬市場における競合情勢の把握

RSV診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスRSV診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、RSV診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨RSV診断薬市場における成功への道筋を描く

RSV診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 人口における呼吸器感染症の罹患率の上昇
    • 感染症の早期診断に対する意識の高まり
    • シンシチウムウイルス診断製品の承認増加
  • 抑制要因
    • RSウイルス診断製品に関連する製品リコール問題
  • 機会
    • RSウイルス診断の進歩
    • ゲノミクスとプロテオミクス調査の成長
  • 課題
    • 現在のRSV診断製品および手順に関連する制限
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 RSV診断薬市場：製品別

• 機器
• キットとアッセイ

第7章 RSV診断薬市場方法別

• 分子診断
• 迅速抗原検出検査

第8章 RSV診断薬市場：最終用途別

• ホームケア
• 病院・クリニック

第9章 南北アメリカのRSV診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のRSV診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのRSV診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Altona Diagnostics GmbH
• Atlas Medical GmbH
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• BTNX Inc.
• CerTest Biotec S.L.
• CTK Biotech, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Merck KGaA
• Meridian Bioscience, Inc.
• Pro-Lab Diagnostics Inc.
• Qiagen GmbH
• Quidel Corporation
• SA Scientific, Ltd.
• Sansure Biotech Inc.
• Sentinel Ch S.p.A.
• Serion GmbH
• Siemens Healthcare GmbH
• Thermo Fisher Scientific Inc.
• Vela Diagnostics Holding Pte Ltd.
• Virax Biolabs Group Limited
• Weldon Biotech, Inc.

LIST OF FIGURES

• FIGURE 1. RSV DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. RSV DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RSV DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES RSV DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES RSV DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. RSV DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. RSV DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RSV DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RSV DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RSV DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN DETECTION TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 26. CANADA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 27. CANADA RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 28. CANADA RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 29. MEXICO RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES RSV DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. AUSTRALIA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 43. CHINA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. CHINA RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 45. CHINA RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 46. INDIA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. INDIA RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 48. INDIA RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 49. INDONESIA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 52. JAPAN RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 55. MALAYSIA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 58. PHILIPPINES RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 61. SINGAPORE RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 64. SOUTH KOREA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 67. TAIWAN RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 70. THAILAND RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 73. VIETNAM RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 80. DENMARK RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 83. EGYPT RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 86. FINLAND RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 89. FRANCE RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 92. GERMANY RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 95. ISRAEL RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 98. ITALY RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. ITALY RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 100. ITALY RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 101. NETHERLANDS RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 104. NIGERIA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 107. NORWAY RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 110. POLAND RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. POLAND RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 112. POLAND RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 113. QATAR RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. QATAR RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 115. QATAR RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 116. RUSSIA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 119. SAUDI ARABIA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH AFRICA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 125. SPAIN RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 128. SWEDEN RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 131. SWITZERLAND RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 134. TURKEY RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 137. UNITED ARAB EMIRATES RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED KINGDOM RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM RSV DIAGNOSTICS MARKET SIZE, BY METHODS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM RSV DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 143. RSV DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 144. RSV DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The RSV Diagnostics Market was valued at USD 1.07 billion in 2023, expected to reach USD 1.17 billion in 2024, and is projected to grow at a CAGR of 9.20%, to USD 1.98 billion by 2030.

Respiratory Syncytial Virus (RSV) diagnostics are crucial in the healthcare landscape due to the virus's impact on infants, elderly, and immunocompromised individuals. The scope of RSV diagnostics encompasses diverse testing methodologies such as rapid antigen detection tests (RADTs), molecular diagnostics like RT-PCR, and serological assays. These play a pivotal role in early detection and management, thereby reducing the transmission and severity of RSV infections. The necessity of RSV diagnostics has surged, driven by increasing global awareness about viral infections and advancements in point-of-care testing technologies. End-use scopes primarily involve hospitals, diagnostic laboratories, and clinics, where efficient and quick decisions are vital for patient care. The market is poised for growth due to factors such as rising RSV prevalence, growing demand for decentralized diagnostic solutions, and advancements in healthcare infrastructure. However, challenges including high costs of advanced diagnostic tools, variability in test sensitivity, and regulatory hurdles can impede growth. Opportunities exist in the development of cost-effective, highly sensitive diagnostic alternatives and the integration of artificial intelligence to enhance accuracy and efficiency of RSV tests. Companies can capitalize on these opportunities by investing in technology-driven product development and expanding into high-growth emerging markets with burgeoning healthcare needs. Research and innovation can focus on enhancing molecular diagnostics, developing portable point-of-care devices, and exploring bioinformatics for predictive diagnostics. Despite the promising outlook, the market faces limitations such as competition from generic diagnostic methods, potential biosafety issues, and economic constraints in low-income regions. Strategic recommendations for businesses include forming partnerships with healthcare providers for broader product reach, focusing on R&D to drive innovation, and ensuring compliance with evolving regulations through strategic planning. The nature of the RSV diagnostics market is dynamic, with a trend towards personalized healthcare solutions, emphasizing the need for continual adaptation and innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving RSV Diagnostics Market

The RSV Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of respiratory infections among population
  • Growing awareness about early diagnosis of infectious diseases
  • Increasing approvals for syncytial virus diagnostic product
• Market Restraints
  • Product recall issues associated with RSV diagnostic products
• Market Opportunities
  • Advancements in respiratory syncytial virus diagnosis
  • Growth in genomics and proteomics research
• Market Challenges
  • Limitations associated with current RSV diagnostic products and procedures

Porter's Five Forces: A Strategic Tool for Navigating the RSV Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the RSV Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the RSV Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the RSV Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the RSV Diagnostics Market

A detailed market share analysis in the RSV Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the RSV Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the RSV Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the RSV Diagnostics Market

A strategic analysis of the RSV Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the RSV Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Altona Diagnostics GmbH, Atlas Medical GmbH, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, BTNX Inc., CerTest Biotec S.L., CTK Biotech, Inc., Danaher Corporation, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Hologic, Inc., Merck KGaA, Meridian Bioscience, Inc., Pro-Lab Diagnostics Inc., Qiagen GmbH, Quidel Corporation, SA Scientific, Ltd., Sansure Biotech Inc., Sentinel Ch S.p.A., Serion GmbH, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Vela Diagnostics Holding Pte Ltd., Virax Biolabs Group Limited, and Weldon Biotech, Inc..

Market Segmentation & Coverage

This research report categorizes the RSV Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Instruments and Kits & Assays.
• Based on Methods, market is studied across Molecular Diagnostics and Rapid Antigen Detection Tests.
• Based on End-use, market is studied across Home Care and Hospital & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of respiratory infections among population
    • 5.1.1.2. Growing awareness about early diagnosis of infectious diseases
    • 5.1.1.3. Increasing approvals for syncytial virus diagnostic product
  • 5.1.2. Restraints
    • 5.1.2.1. Product recall issues associated with RSV diagnostic products
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in respiratory syncytial virus diagnosis
    • 5.1.3.2. Growth in genomics and proteomics research
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations associated with current RSV diagnostic products and procedures
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. RSV Diagnostics Market, by Product

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Kits & Assays

7. RSV Diagnostics Market, by Methods

• 7.1. Introduction
• 7.2. Molecular Diagnostics
• 7.3. Rapid Antigen Detection Tests

8. RSV Diagnostics Market, by End-use

• 8.1. Introduction
• 8.2. Home Care
• 8.3. Hospital & Clinics

9. Americas RSV Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific RSV Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa RSV Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Altona Diagnostics GmbH
• 3. Atlas Medical GmbH
• 4. Becton, Dickinson and Company
• 5. Bio-Rad Laboratories, Inc.
• 6. bioMerieux SA
• 7. BTNX Inc.
• 8. CerTest Biotec S.L.
• 9. CTK Biotech, Inc.
• 10. Danaher Corporation
• 11. DiaSorin S.p.A.
• 12. F. Hoffmann-La Roche Ltd.
• 13. Hologic, Inc.
• 14. Merck KGaA
• 15. Meridian Bioscience, Inc.
• 16. Pro-Lab Diagnostics Inc.
• 17. Qiagen GmbH
• 18. Quidel Corporation
• 19. SA Scientific, Ltd.
• 20. Sansure Biotech Inc.
• 21. Sentinel Ch S.p.A.
• 22. Serion GmbH
• 23. Siemens Healthcare GmbH
• 24. Thermo Fisher Scientific Inc.
• 25. Vela Diagnostics Holding Pte Ltd.
• 26. Virax Biolabs Group Limited
• 27. Weldon Biotech, Inc.